Originally founded in 1996 as Trinity Partners, Trinity Life Sciences (Trinity) has since grown to comprise a global team of advisors, technical experts, data integrators, and technology innovators. Trinity’s vision is to be the premier global life sciences commercialization partner, empowering clients to deliver life-changing therapies to patients.
Trinity’s approach is focused on the company’s foundation of three: advisory services, insights & analytics, and technology. By seamlessly integrating each of these solutions, Trinity can meet the distinct needs of both emerging biotech firms and established pharmaceutical companies.
Trinity can provide comprehensive end-to-end analytical and strategic support to early-stage companies as well as tools and solutions for larger, more established life sciences clients. Trinity’s recent activities to expand its commercialization capabilities include:
Trinity announced a partnership with Komodo Health that will unlock unique, valuable insights in combination with Trinity’s EvidenceFirst. Trinity’s experts leverage EvidenceFirst, a suite of real-world evidence (RWE) offerings, to help pharma, biotech, and medtech companies navigate to strategic, data-informed decisions across an asset’s lifecycle.
Komodo’s Healthcare Map™ is the industry’s largest and most complete database of de-identified, real-world patient data, and tracks more than 330 million patient journeys. Already a powerful source of RWE solutions, EvidenceFirst will now use Komodo software to draw from the Healthcare Map’s unmatched view of patients to deliver relevant and actionable insights life sciences clients need to answer core and evolving business questions.
Trinity recently announced the acquisition of CBPartners. The acquisition significantly scales Trinity’s Value, Access and Pricing business, adding over 75 dedicated experts to the company. The combination of Trinity’s commercial strategy and solutions, augmented by CBPartners’ expertise in the value, access and pricing space, will better empower life sciences companies to commercialize their innovations and ensure access for patients.
CBPartners’ senior leadership and staff will remain on with Trinity, and the addition of the CBPartners consultants will significantly expand Trinity’s footprint in New York City, San Francisco and London. The aligned cultures and values of both companies reflect an evidence-first approach to helping clients make critical business decisions.
Trinity also announced a new partnership that enables Trinity EvidenceFirst to unlock streamlined, integrated insights using Forian’s real-world data (RWD) products. Trinity’s new partnership with Forian will provide life sciences companies with the exact expertise and data they need to answer core and evolving business questions.
By creating health information offerings through clinical evidence in real-world settings, Forian collaborates with partners to provide premier solutions that determine actionable insights from historical data patterns, future trends and likely outcomes for patients.
Takeaway: Trinity’s recent activities positions the company to help clients revolutionize the commercial model and provide their drugs to patients around the world